Literature DB >> 17599806

Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer.

Shin Maeda1, Yohko Hikiba, Wataru Shibata, Tomoya Ohmae, Ayako Yanai, Keiji Ogura, Shingo Yamada, Masao Omata.   

Abstract

High-mobility group box 1 (HMGB1) is a nuclear factor released extracellularly as a proinflammatory cytokine. We measured the HMGB1 concentration in the sera of mice with chemically induced colitis (DSS; dextran sulfate sodium salt) and found a marked increase. Inhibition of HMGB1 by neutralizing anti-HMGB1 antibody resulted in reduced inflammation in DSS-treated colons. In macrophages, HMGB1 induces several proinflammatory cytokines, such as IL-6, which are regulated by NF-kappaB activation. Two putative sources of HMGB1 were explored: in one, bacterial factors induce HMGB1 secretion from macrophages and in the other, necrotic epithelial cells directly release HMGB1. LPS induced a small amount of HMGB1 in macrophages, but macrophages incubated with supernatant prepared from necrotic cells and containing large amounts of HMGB1 activated NF-kappaB and induced IL-6. Using the colitis-associated cancer model, we demonstrated that neutralizing anti-HMGB1 antibody decreases tumor incidence and size. These observations suggest that HMGB1 is a potentially useful target for IBD treatment and the prevention of colitis-associated cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17599806     DOI: 10.1016/j.bbrc.2007.06.065

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  55 in total

Review 1.  Immunopathogenesis of IBD: current state of the art.

Authors:  Heitor S P de Souza; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-02       Impact factor: 46.802

Review 2.  Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.

Authors:  Geetha Srikrishna; Hudson H Freeze
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

Review 3.  Alarmins: awaiting a clinical response.

Authors:  James K Chan; Johannes Roth; Joost J Oppenheim; Kevin J Tracey; Thomas Vogl; Marc Feldmann; Nicole Horwood; Jagdeep Nanchahal
Journal:  J Clin Invest       Date:  2012-08-01       Impact factor: 14.808

4.  Intestinal epithelial HMGB1 inhibits bacterial infection via STAT3 regulation of autophagy.

Authors:  Yong-Guo Zhang; Xiaorong Zhu; Rong Lu; Jeannette S Messer; Yinglin Xia; Eugene B Chang; Jun Sun
Journal:  Autophagy       Date:  2019-04-09       Impact factor: 16.016

5.  Helicobacter pylori VacA induces programmed necrosis in gastric epithelial cells.

Authors:  Jana N Radin; Christian González-Rivera; Susan E Ivie; Mark S McClain; Timothy L Cover
Journal:  Infect Immun       Date:  2011-04-11       Impact factor: 3.441

Review 6.  Inflammation in osteoarthritis: is it time to dampen the alarm(in) in this debilitating disease?

Authors:  M H J van den Bosch
Journal:  Clin Exp Immunol       Date:  2018-11-28       Impact factor: 4.330

7.  Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels.

Authors:  Xiugui Sheng; Xuelian Du; Xiaoling Zhang; Dapeng Li; Chunhua Lu; Qinshui Li; Zhifang Ma; Quqing Song; Cong Wang
Journal:  Croat Med J       Date:  2009-10       Impact factor: 1.351

Review 8.  Targeting HMGB1 in inflammation.

Authors:  Huan Yang; Kevin J Tracey
Journal:  Biochim Biophys Acta       Date:  2009-12-03

9.  Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis.

Authors:  Shaival H Davé; Jeremy S Tilstra; Katsuyoshi Matsuoka; Fengling Li; Richard A DeMarco; Donna Beer-Stolz; Antonia R Sepulveda; Mitchell P Fink; Michael T Lotze; Scott E Plevy
Journal:  J Leukoc Biol       Date:  2009-05-19       Impact factor: 4.962

10.  Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer.

Authors:  Hye Won Chung; Sang-Guk Lee; Heejung Kim; Duck Jin Hong; Jae Bock Chung; David Stroncek; Jong-Baeck Lim
Journal:  J Transl Med       Date:  2009-05-28       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.